# WIN SYMPOSIUM 29-30 October 2022 Barcelona, Spain INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY: A WINNING STRATEGY

			Saturday October 29
VELCOM	IE AND OPENING REMARKS		
	08:30 Welcome and opening remarks	Richard L. Schilsky	Chairman WIN Consortium, Chevilly-Larue, France
		Josep Tabernero	Vice-Chairman WIN Consortium, Vall d'Hebron Institute d Oncology (VHIO), Barcelona, Spain
	<b>08:50 Opening Keynote Lecture</b> Re-imagining the (r)evolution in the Precision Oncology paradigm: the future is now	Vivek Subbiah	The University of Texas, MD Anderson Cancer Center, Houston, USA
ESSION	1 - BEYOND DNA TESTING: THE PLACE OF TR	ANSCRIPTOMICS IN	PRECISION ONCOLOGY
Chairs: Yv	ves Lussier	Ioana Berindea	
hairman, W	IN Scientific Advisory Board, University of Utah School of Medicine, US	A University of Medicine	and Pharmacy Iuliu Hatieganu, Cluj, Romania
	<b>09:20 Keynote Lecture</b> Rational development of targeted therapies to cure molecular subtypes of diffuse large B cell lymphoma (DLBCL)	Louis M. Staudt	National Cancer Institute (NCI), Bethesda, USA
	09:50 Keynote Lecture	_ ,_	
	Functional genomics to identify cancer vulnerabilities	René Bernards	Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
	10:20 Accelerating precision oncology using multi-omics and Al	Olivier Elemento	Weill Cornell Medicine, New York, USA
0:50 Coffee	e break, networking		
	11:15 Next generation transcriptomics-based Precision Oncology	Eytan Ruppin	National Institute of Health (NIH), Bethesda, USA
	11:40 SIMS and Digital Display Precision Predictor algorithms	Vladimir Lazar	WIN Consortium, Chevilly-Larue, France
	12:05 Modeling gene regulatory processes to understand cancer and identify therapies	John Quackenbush	Harvard T.H. Chan School of Public Health, Boston, USA
2:35 Panel	Discussion		
3:00 Lunch	n, poster viewing and networking		
SESSION	2 – INNOVATION IN CLINICAL TRIALS TO ENA	ABLE FUTURE EFFICI	ENT TREATMENTS
Chairs: H	ikmat Abdel-Razeq Cristia	no de Pádua Souza	
ing Hussei		io Pio XII – Hospital do Can	cer de Barretos, Brazil
	14:30 Keynote opening Lecture Bringing single cell analyses to the clinics	Andrea Califano	Columbia University Medical Center, New York, USA
	15:00 Keynote lecture Identifying new uses for approved, targeted drugs: Updates from the ASCO TAPUR study	Richard L. Schilsky	WIN Consortium, Chevilly-Larue, France
	15:25 Genomic and transcriptomic signatures and innovation in CRC cancers	Josep Tabernero	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
9	<b>15:50</b> Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses	Jean-François Martini	Pfizer, Inc., San Diego, USA
	<b>16:15</b> IO in combination: the SPRING tri-therapy approach	Benjamin Solomon	Avera Cancer Institute, Sioux Falls, USA
6:40 Coffee	l e break, networking		
0.40 (0))			

18:00 Poster viewing

20:00 Symposium Dinner

## **Sunday October 30**

## SESSION 3 – DISRUPTIVE CONCEPTS AND METHODOLOGICAL INNOVATIONS IN NSCLC: MEET THE EXPERTS

Chairs: Pierre Saintigny

**Gerald Batist** 

Centre Léon Bérard, Lyon, France Segal Cancer Center, Canac

O8:30 Keynote lecture Overview of advances in lung cancer	Enriqueta Felip	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
<b>08:55</b> From chest x ray to Al-assisted lung cancer screening and early detection program in Israel	Amir Onn	Sheba Medical Center, Ramat Gan, Israel
<b>09:20</b> Individualized surgical treatment strategy for early-stage lung cancer: Translation of knowledge	Haiquan Chen	Fudan University, Shanghai, China
09:45 Neoadjuvant and adjuvant strategies in NSCLC	Jair Bar	Sheba Medical Center, Ramat Gan, Israel
10:10 New drugs for SCLC	Pilar Garrido	Universidad de Alcalá, Madrid, Spain
	Overview of advances in lung cancer  08:55 From chest x ray to Al-assisted lung cancer screening and early detection program in Israel  09:20 Individualized surgical treatment strategy for early-stage lung cancer: Translation of knowledge  09:45 Neoadjuvant and adjuvant strategies in NSCLC	Overview of advances in lung cancer  08:55 From chest x ray to Al-assisted lung cancer screening and early detection program in Israel  09:20 Individualized surgical treatment strategy for early-stage lung cancer: Translation of knowledge  09:45 Neoadjuvant and adjuvant strategies in NSCLC  Enriqueta Felip  Amir Onn  Haiquan Chen

10:35 Panel Discussion and Q&A from the audience

11:00 Coffee Break, networking

## SESSION 4 - WIN FIRST INTERNATIONAL MOLECULAR TUMOR BOARD: A STRATEGIC PLACE IN ADVANCING PRECISION ONCOLOGY

	CARD.	
٦		
7		
7		

11:30 First WIN International Molecular Tumor Board Introduction Case presentation by investigators. Panel Discussion and Q&A from the audience Moderator:
Razelle Kurzrock
Case presentations:
Wafik S. El-Deiry
Maria Vieito
Panel:
Wafik S. El-Deiry
Enriqueta Felip
Ulrik Lassen
Vivek Subbiah

WIN Consortium, Chevilly-Larue, France

Rigshospitalet, Copenhagen, Denmark

Legorreta Cancer Center at Brown University, USA

VHIO, Barcelona, Spain

Legorreta Cancer Center at Brown University, Providence VHIO, Barcelona, Spain

The University of Texas, MD Anderson Cancer Center, USA

13:00 Lunch, poster viewing and networking

### SESSION 5 - WHAT IS NEW IN BREAST, CRC, HEAD & NECK and PEDIATRIC CANCERS?

**Chairs: Michel Ducreux** 

**Ulrik Lassen** 

Chairs. Whener Ducteux			
<b>Gustave Rous</b>	sy, France Rigshospitalet, De	nmark	
	14:00 Opening Keynote Lecture Precision Medicine for patients with metastatic breast cancer	Fabrice André	Gustave Roussy, Villejuif, France
	14:25 Keynote Lecture  Novel CRC insights based on combined genomic and transcriptomic data at both bulk and single cell level, leading to new therapeutically relevant CRC classification	Sabine Tejpar	University of Leuven, Belgium
	14:50 Beyond the tip of the iceberg: proteomic analysis in colon and breast cancer	Gerald Batist	Segal Cancer Centre, Lady Davis Institute at the JGH, McGill University, Montréal, Canada
	<b>15:15</b> Proteogenomic analysis of triple negative breast cancer (TNBC) response to neoadjuvant chemotherapy	Matthew Ellis	AstraZeneca, Gaithersburg, USA
	15:40 Novel strategies in head & neck cancers	Christophe Le Tourneau	Institut Curie, Paris, France
	<b>16:05</b> Pediatric European Precision Cancer Medicine Program - Facing cancer complexity	Birgit Geoerger	Gustave Roussy, Villejuif, France ITCC

16:30 Panel Discussion and Q&A from the audience



#### 16:55 BEST TWO POSTERS' PRESENTATIONS AND AWARDS

Josep Tabernero, Vice-Chairman WIN Consortium, Vall d'Hebron Institute of Oncology (VHIO); Amir Onn, Head of the Standard Operating Procedures and Repository Committee, WIN Consortium; Chair, Institute of Pulmonary Medicine, Sheba Medical Center, Israel



17:20 CONCLUSIONS

Richard L. Schilsky, Chairman WIN Consortium